Daptomycin Market size was estimated at over USD 3.4 billion in 2024 and is poised to reach USD 5.1 billion by the end of 2037, expanding at a CAGR of 3.5% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of daptomycin is evaluated at USD 3.5 billion.
The proven efficacy of this element as an antibiotic solution is driving growth in the daptomycin market. The rising prevalence of bacterial infection, particularly during hospital stays inflates the demand for such therapeutics. According to a WHO report, published in May 2022, around 7 in high-income countries and 15 in low- and middle-income countries are affected by healthcare-associated infection (HAI) among every 100 patients admitted to acute-care hospitals. The report further stated that 24% of the total HAI patients and 52.3% of these affected patients being treated in an ICU die every year. Thus, growing mortality cases are concerning the public healthcare associations, pushing them to invest in availing effective treatments.
In addition, these infections often develop capabilities to resist antibiotic therapies, increasing the need for specific therapeutics. The offerings from the daptomycin market are well-efficient in combating such resistant bacterial strains, resulting in higher utilization. Moreover, growing reliance on advanced antibiotic products is creating a surge in this sector. According to the 2022 OEC data, the global trade value of antibiotics rose by 2.1% from 2021, reaching USD 10.7 billion in 2022. The exponential expansion of this industry is further inspiring pharmaceutical leaders to introduce more effective solutions such as daptomycin for solidifying their positions in the global landscape of this sector.
Growth Drivers
|
Infection Type |
Success Rate |
Mortality Rate |
|
Device-related Endocarditis |
80% |
0% |
|
MSRA Bacteremia |
84% |
6.1% |
|
Osteomyelitis and Prosthetic Joint Infections |
85% |
0% |
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
3.5% |
|
Base Year Market Size (2024) |
USD 3.4 billion |
|
Forecast Year Market Size (2037) |
USD 5.1 billion |
|
Regional Scope |
|
Strength (300mg, 500mg)
Based on strength, 500mg segment is projected to hold daptomycin market share of more than 78.4% by 2037. This drug works as an excellent indicator for Gram-positive infections such as skin and soft tissue infections (SSTIs), bacteremia, and endocarditis. This specific formulation of the medicine is effective for a wide range of chronic bacterial attacks such as bacteremia and endocarditis. Thus, the increasing prevalence of HAIs and antibiotic resistance is driving demand for this segment, inspiring pharma companies to introduce more of these formulations. For instance, in September 2019, Cipla launched a daptomycin Injection, 500mg/vial to beat the sales of Cubicin in the U.S., worth USD 606 million.
Indication (Complicated Skin Structure Infections, Bacteremia)
In terms of indication, the complicated skin structure infections segment is projected to garner a significant share of the daptomycin market during the forecast period. This segment is pledged with the growing need for advanced antibiotics to cure such medical conditions. Clinical evidence of higher positive results in treating gram-positive pathogens, particularly MRSA multi-drug-resistant bacteria makes daptomycin preferable, inspiring companies to develop more effective solutions. For instance, in October 2021, Pfizer Hospital unveiled an additional formulation for both of its daptomycin injections of 350 mg and 500 mg strength. This formula features a faster and no-refrigeration constitution, while efficiently indicating cSSSI and bacteremia in adult patients.
Our in-depth analysis of the global market includes the following segments:
|
Strength |
|
|
Indication |
|
|
Application |
|
North America Market Analysis
North America in daptomycin market is anticipated to account for more than 49% revenue share by the end of 2037. Advanced healthcare infrastructure and increased expenditure for controlling the spread of HAIs are the major growth factors in this landscape. According to a report published by the U.S. Department of Health and Human Services, in 2020, sepsis is the major reason behind the illness of 1.7 million and the death of 270,000 people annually. The report further stated that around 258 million antibiotic prescriptions were issued from the OPD pharmacy terminals in the U.S. in 2017. This highlights the growing need for advanced antimicrobial drugs such as daptomycin in this region.
The U.S. has become the hub for global leaders in the daptomycin market due to its wide consumer base and excellent distribution channels. The country presents a golden opportunity for them to expand their business, making a crucial step in globalization. This further inspires other domestic participants to establish their footprint in this country by promoting the effectiveness of this drug. For instance, in July 2020, Sandoz Inc. launched daptomycin for injection of 500 mg in the U.S. to expand its injectable portfolio. This AP-rated generic version of Cubicin can treat cSSSI and some of the bloodstream infections.
Canada is steadily consolidating its position in the daptomycin market with proactive government initiatives and subsidiary policies. The concerning growth in HAI mortality cases is pushing the country to promote available treatment options and preventive measures. For instance, in May 2023, the government of Canada announced an investment of USD 6.3 million in antibiotic R&D to win the battle against the Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X). This is further inflating demand in this sector due to the proven efficacy of daptomycin therapeutics in treating infectious conditions.
APAC Market Statistics
Asia Pacific is expected to demonstrate the fastest growth in the daptomycin market with its strong captivity in biotechnology and R&D in microbials. The region is augmenting such growth with the developmental tendency of countries such as China, India, Japan, and Australia. The governing bodies in these countries are inspiring domestic leaders to elevate their production and supply across the world to take leadership in this sector. Thus, the growth in this region is further carried forward with the efforts of regional pharma leaders who are conducting R&D to bring innovations in this field.
India is propagating the regional daptomycin market with its strong pharmaceutical development and expansion. The country is accumulating the resources to leverage the accessibility of generic antibiotics. In addition, the rising burden of resistant pathogens in medical facilities across the country is fueling this sector. According to the 2022 OEC data, India became the 2nd largest exporter of antibiotics worldwide, achieving a value of USD 923 million. The country also accounted for the largest importer of these products, reaching USD 1.4 billion.
China is one of the biggest suppliers of the daptomycin market which is emerging as a great distribution source of this region. The country is also aiming to introduce more cost-effective solutions through mass production, offering a favorable business environment for both domestic and international leaders. According to the 2022 OEC data, China gained an export value of USD 4.5 billion for antibiotic products, making it the largest exporter of this category in the world. The report further highlighted the top export destinations to be India, Vietnam, Brazil, the U.S., and Italy.
The competitive demographic of the daptomycin market is inspiring global leaders to enforce their financial and academic resources in innovating more effective solutions. They are continuously putting efforts to promote adoption to push their territory forward for globalization. This is further dragging the focus of other competitor pharma companies to participate, enlarging the boundaries of this sector. For instance, in August 2024, Sunshine Biopharma, Inc. launched a new line of generic medicines, consisting of 9 prescription drugs in Canada. The pipeline contains several clinically proven drugs including daptomycin which is to be marketed and distributed in the country by its wholly owned subsidiary, Nora Pharma. Such key players include:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?